Vanguard Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$26.7M Buy
2,787,311
+8,624
+0.3% +$82.7K ﹤0.01% 2420
2025
Q1
$17.4M Sell
2,778,687
-874
-0% -$5.48K ﹤0.01% 2566
2024
Q4
$22.6M Buy
2,779,561
+83,238
+3% +$676K ﹤0.01% 2530
2024
Q3
$48.7M Buy
2,696,323
+484,568
+22% +$8.76M ﹤0.01% 2189
2024
Q2
$22.8M Buy
2,211,755
+232,642
+12% +$2.4M ﹤0.01% 2506
2024
Q1
$21M Buy
1,979,113
+22,684
+1% +$241K ﹤0.01% 2571
2023
Q4
$17.9M Buy
1,956,429
+33,767
+2% +$308K ﹤0.01% 2647
2023
Q3
$19.9M Buy
1,922,662
+180,325
+10% +$1.87M ﹤0.01% 2554
2023
Q2
$25M Buy
1,742,337
+564,840
+48% +$8.09M ﹤0.01% 2501
2023
Q1
$8.41M Buy
1,177,497
+100,892
+9% +$720K ﹤0.01% 3032
2022
Q4
$12.1M Buy
1,076,605
+106,851
+11% +$1.2M ﹤0.01% 2870
2022
Q3
$10.7M Sell
969,754
-915,098
-49% -$10.1M ﹤0.01% 2930
2022
Q2
$15.9M Sell
1,884,852
-57,849
-3% -$488K ﹤0.01% 2759
2022
Q1
$26.4M Buy
1,942,701
+14,857
+0.8% +$202K ﹤0.01% 2625
2021
Q4
$37.9M Buy
1,927,844
+114,193
+6% +$2.25M ﹤0.01% 2503
2021
Q3
$58.2M Buy
1,813,651
+254,362
+16% +$8.16M ﹤0.01% 2282
2021
Q2
$52.8M Buy
1,559,289
+79,697
+5% +$2.7M ﹤0.01% 2345
2021
Q1
$55.6M Buy
1,479,592
+38,655
+3% +$1.45M ﹤0.01% 2256
2020
Q4
$47.9M Buy
1,440,937
+698,588
+94% +$23.2M ﹤0.01% 2224
2020
Q3
$27.2M Buy
742,349
+43,230
+6% +$1.59M ﹤0.01% 2308
2020
Q2
$23M Buy
699,119
+493,607
+240% +$16.2M ﹤0.01% 2355
2020
Q1
$5.31M Sell
205,512
-483
-0.2% -$12.5K ﹤0.01% 2950
2019
Q4
$6.42M Buy
+205,995
New +$6.42M ﹤0.01% 3079